Skip to main content
Top
Published in: BMC Pediatrics 1/2017

Open Access 01-12-2017 | Research article

Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants

Authors: Cristiane Kopacek, Simone Martins de Castro, Mayara Jorgens Prado, Claudia Maria Dornelles da Silva, Luciana Amorim Beltrão, Poli Mara Spritzer

Published in: BMC Pediatrics | Issue 1/2017

Login to get access

Abstract

Background

Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder associated with inborn errors of steroid metabolism. 21-hydroxylase enzyme deficiency occurs in 90 to 95% of all cases of CAH, with accumulation of 17 hydroxyprogesterone (17-OHP). Early diagnosis of CAH based on newborn screening is possible before the development of symptoms and allows proper treatment, correct sex assignment, and reduced mortality rates. This study describes the results obtained in the first year of a public CAH screening program in the state of Rio Grande do Sul, Brazil.

Methods

We reviewed the screening database in search of babies with suspected CAH, that is, altered birth-weight adjusted 17-OHP values at screening. The following data were analyzed for this population: screening 17-OHP values, retest 17-OHP values, serum 17-OHP values for those with confirmed CAH on retest, maternal and newborn data, and family history of CAH. For the screening program, 17-OHP levels are determined on dried blood spots obtained in filter paper with GSP solid phase time-resolved immunofluorescence.

Results

Of 108,409 newborns screened, eight were diagnosed with CAH (four males, four females). The incidence of CAH in the state was 1:13,551. Six cases were identified as classic salt-wasting CAH and two were cases of virilizing CAH. The positive predictive value (PPV) of the initial screening (before diagnostic confirmation) was 1.6%. The overall rate of false positive results was 0.47%. The number of false positive results was higher among newborns with birth weight < 2000 g.

Conclusion

The present results support the need for CAH screening by the public health care system in the state, and show that the strategy adopted is adequate. PPV and false positive results were similar to those reported for other states of Brazil with similar ethnic backgrounds.
Literature
1.
go back to reference White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21(3):245–91.PubMed White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21(3):245–91.PubMed
2.
go back to reference Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(9):4133–60.CrossRefPubMedPubMedCentral Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(9):4133–60.CrossRefPubMedPubMedCentral
3.
go back to reference Bachega TA, Billerbeck AE, Parente EB, Lemos-Marini SH, Baptista MT, Mello MP, Guerra Jr G, Kuperman H, Setian N, Damiani D, Torres N, Castro M, Mendonça BB. Multicentric study of Brazilian patients with 21-hydroxylase deficiency: a genotypephenotype correlation. Arq Bras Endocrinol Metabol. 2004;48(5):697–704.CrossRefPubMed Bachega TA, Billerbeck AE, Parente EB, Lemos-Marini SH, Baptista MT, Mello MP, Guerra Jr G, Kuperman H, Setian N, Damiani D, Torres N, Castro M, Mendonça BB. Multicentric study of Brazilian patients with 21-hydroxylase deficiency: a genotypephenotype correlation. Arq Bras Endocrinol Metabol. 2004;48(5):697–704.CrossRefPubMed
4.
go back to reference Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab. 2002;87(9):4048–53.CrossRef Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab. 2002;87(9):4048–53.CrossRef
5.
go back to reference Speiser PW. Prenatal and neonatal diagnosis and treatment of congenital adrenal hyperplasia. Horm Res. 2007;68(5):90–2.PubMed Speiser PW. Prenatal and neonatal diagnosis and treatment of congenital adrenal hyperplasia. Horm Res. 2007;68(5):90–2.PubMed
6.
go back to reference Pang SY, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon IC, Dobbins RH, Kling S, Fujieda K, Suwa S. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988;81(6):866–74.PubMed Pang SY, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon IC, Dobbins RH, Kling S, Fujieda K, Suwa S. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988;81(6):866–74.PubMed
7.
go back to reference Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997;130(1):128–33.CrossRefPubMed Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997;130(1):128–33.CrossRefPubMed
8.
go back to reference Nordenström A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics. 2001;108(4):E68.CrossRefPubMed Nordenström A, Wedell A, Hagenfeldt L, Marcus C, Larsson A. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics. 2001;108(4):E68.CrossRefPubMed
9.
go back to reference Olgemöller B, Roscher AA, Liebl B, Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab. 2003;88(12):5790–4.CrossRefPubMed Olgemöller B, Roscher AA, Liebl B, Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab. 2003;88(12):5790–4.CrossRefPubMed
10.
go back to reference Hayashi G, Faure C, Brondi MF, Vallejos C, Soares D, Oliveira E, Brito VN, Mendonca BB, Bachega TA. Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasia. Arq Bras Endocrinol Metabol. 2011;55(8):632–7.CrossRefPubMed Hayashi G, Faure C, Brondi MF, Vallejos C, Soares D, Oliveira E, Brito VN, Mendonca BB, Bachega TA. Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasia. Arq Bras Endocrinol Metabol. 2011;55(8):632–7.CrossRefPubMed
11.
go back to reference Tsuji A, Konishi K, Hasegawa S, Anazawa A, Onishi T, Ono M, Morio T, Kitagawa T, Kashimada K. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr. 2015;15(1):209.CrossRefPubMedPubMedCentral Tsuji A, Konishi K, Hasegawa S, Anazawa A, Onishi T, Ono M, Morio T, Kitagawa T, Kashimada K. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr. 2015;15(1):209.CrossRefPubMedPubMedCentral
12.
go back to reference Pauwels G, Allegaert NK, Régal L, Meulemans A. Risk factors for elevated levels of 17-hydroxyprogesterone during neonatal intensive care unit admission. Acta Clin Belg. 2012;67(2):88–93.PubMed Pauwels G, Allegaert NK, Régal L, Meulemans A. Risk factors for elevated levels of 17-hydroxyprogesterone during neonatal intensive care unit admission. Acta Clin Belg. 2012;67(2):88–93.PubMed
13.
go back to reference Gatelais F, Berthelot J, Beringue F, Descamps P, Bonneau D, Limal JM, Coutant R. Effect of single and multiple courses of prenatal corticosteroids on 17 hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia. Pediatr Res. 2004;56(5):701–5.CrossRefPubMed Gatelais F, Berthelot J, Beringue F, Descamps P, Bonneau D, Limal JM, Coutant R. Effect of single and multiple courses of prenatal corticosteroids on 17 hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia. Pediatr Res. 2004;56(5):701–5.CrossRefPubMed
14.
go back to reference Sarafoglou K, Banks K, Gaviglio A, Hietala A, McCann M, Thomas W. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia. Pediatrics. 2012;130(5):e1261–8. doi:10.1542/peds.2012-1219. Epub 2012 Oct 15.CrossRefPubMed Sarafoglou K, Banks K, Gaviglio A, Hietala A, McCann M, Thomas W. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia. Pediatrics. 2012;130(5):e1261–8. doi:10.​1542/​peds.​2012-1219. Epub 2012 Oct 15.CrossRefPubMed
16.
go back to reference Barra CB, Silva IN, Pezzuti IL, Januário JN. Neonatal screening for congenital adrenal hyperplasia. Rev Assoc Med Bras. 2012;58(4):459–64.CrossRefPubMed Barra CB, Silva IN, Pezzuti IL, Januário JN. Neonatal screening for congenital adrenal hyperplasia. Rev Assoc Med Bras. 2012;58(4):459–64.CrossRefPubMed
17.
go back to reference Pezzuti IL, Barra CB, Mantovani RM, Januário JN, Silva IN. A three-year follow-up of congenital adrenal hyperplasia newborn screening. J Pediatr. 2014;90(3):300–407.CrossRef Pezzuti IL, Barra CB, Mantovani RM, Januário JN, Silva IN. A three-year follow-up of congenital adrenal hyperplasia newborn screening. J Pediatr. 2014;90(3):300–407.CrossRef
18.
go back to reference Silveira EL, dos Santos EP, Bachega TA, van der Linden Nader I, Gross JL, Elnecave RH. The actual incidence of congenital adrenal hyperplasia in Brazil may not be as high as inferred—an estimate based on a public neonatal screening program in the state of Goiás. J Pediatr Endocrinol Metab. 2008;21(5):455–60.CrossRefPubMed Silveira EL, dos Santos EP, Bachega TA, van der Linden Nader I, Gross JL, Elnecave RH. The actual incidence of congenital adrenal hyperplasia in Brazil may not be as high as inferred—an estimate based on a public neonatal screening program in the state of Goiás. J Pediatr Endocrinol Metab. 2008;21(5):455–60.CrossRefPubMed
19.
go back to reference Nascimento ML, Cristiano AN, Campos T, Ohira M, Cechinel E, Simoni G, Lee J, Linhares RM, Silva PC. Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia. Arq Bras Endocrinol Metabol. 2014;58(7):765–71.CrossRefPubMed Nascimento ML, Cristiano AN, Campos T, Ohira M, Cechinel E, Simoni G, Lee J, Linhares RM, Silva PC. Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia. Arq Bras Endocrinol Metabol. 2014;58(7):765–71.CrossRefPubMed
20.
go back to reference Triagem neonatal: hiperplasia adrenal congênita/Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Especializada e Temática.–Brasília: Ministério da Saúde, 2015. 44 p. : il. Editora MS–OS 2015/0241 ISBN 978-85-334-2262-9. Printed in Brazil. Triagem neonatal: hiperplasia adrenal congênita/Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Especializada e Temática.–Brasília: Ministério da Saúde, 2015. 44 p. : il. Editora MS–OS 2015/0241 ISBN 978-85-334-2262-9. Printed in Brazil.
22.
go back to reference Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977;45:1003–100.CrossRefPubMed Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977;45:1003–100.CrossRefPubMed
23.
go back to reference Cartigny-Maciejewski M, Guilley N, Vanderbecken S, Gondé S, Stuckens C, Ponté C, Weill J, Farriaux JP, Paux E. Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980–1996. Arch Pediatr. 1999;6(2):151–8.CrossRefPubMed Cartigny-Maciejewski M, Guilley N, Vanderbecken S, Gondé S, Stuckens C, Ponté C, Weill J, Farriaux JP, Paux E. Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980–1996. Arch Pediatr. 1999;6(2):151–8.CrossRefPubMed
25.
go back to reference Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, Lymp J, Hahn SH, Rinaldo P, Matern D. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem. 2004;50(3):621–5.CrossRefPubMed Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, Lymp J, Hahn SH, Rinaldo P, Matern D. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem. 2004;50(3):621–5.CrossRefPubMed
26.
go back to reference Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res. 2009;66:230–5.CrossRefPubMed Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res. 2009;66:230–5.CrossRefPubMed
28.
go back to reference Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y, et al. DHCSF Study Group Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med. 2012;166:113–20.CrossRefPubMed Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y, et al. DHCSF Study Group Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch Pediatr Adolesc Med. 2012;166:113–20.CrossRefPubMed
30.
go back to reference Gidlof S, Wedell A, Guthenberg C, von Dobeln U, Nordenstrom A. Nationwide Neonatal Screening for Congenital Adrenal Hyperplasia in Sweden: A 26-Year Longitudinal Prospective Population-Based Study. JAMA Pediatr. 2014;168(6):567–74.CrossRefPubMed Gidlof S, Wedell A, Guthenberg C, von Dobeln U, Nordenstrom A. Nationwide Neonatal Screening for Congenital Adrenal Hyperplasia in Sweden: A 26-Year Longitudinal Prospective Population-Based Study. JAMA Pediatr. 2014;168(6):567–74.CrossRefPubMed
31.
go back to reference Alves CA, Junior VB, Toralles MB. Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone. Braz J Promot (RBPS). 2006;19(4):203–8. Alves CA, Junior VB, Toralles MB. Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone. Braz J Promot (RBPS). 2006;19(4):203–8.
32.
33.
go back to reference Lee JE, Moon Y, Lee MH, Jun YH, Oh KI, Choi JW. Corrected 17-alpha hydroxyprogesterone values adjusted by a scoring system for screening congenital adrenal hyperplasia in premature infants. Ann Clin Lab Sci. 2008;38(3):235–40.PubMed Lee JE, Moon Y, Lee MH, Jun YH, Oh KI, Choi JW. Corrected 17-alpha hydroxyprogesterone values adjusted by a scoring system for screening congenital adrenal hyperplasia in premature infants. Ann Clin Lab Sci. 2008;38(3):235–40.PubMed
Metadata
Title
Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants
Authors
Cristiane Kopacek
Simone Martins de Castro
Mayara Jorgens Prado
Claudia Maria Dornelles da Silva
Luciana Amorim Beltrão
Poli Mara Spritzer
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2017
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-016-0772-x

Other articles of this Issue 1/2017

BMC Pediatrics 1/2017 Go to the issue